Cyprotex PLC (AIM:CRX), a specialist Contract Research Organisation (CRO), announced today the launch of a new Biosciences division to complement its existing ADME-Tox business.
The new Biosciences division enables customers to access Cyprotex’s expertise in 2D and 3D cell-based efficacy screening to investigate the therapeutic or biological effect of new molecules. These cell-based assays are developed using Cyprotex’s experience in techniques such as high content screening, microelectrode array, and cellular bioenergetics. Cyprotex has already been involved in developing several of these screening assays but, until now, has not actively promoted them.
Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments: ‘We are finding that customers are utilising our experience in existing specialist technologies for efficacy based screening activities. Introducing a Biosciences division is a natural progression from ADME-Tox, allowing us to further diversify our business without significant investment, and enabling us to expand into a new customer base.’
For further information:
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1000 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services as well as the new Biosciences division. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company’s core capabilities include high quality in vitro ADME screening services, in vitro bioscience services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.